These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23122221)

  • 1. Dystrophic tendon functionality is recovered by muscle-specific expression of insulin-like growth factor in mdx mice.
    Rizzuto E; Catizone A; Musarò A; Del Prete Z
    J Biomech; 2013 Feb; 46(3):604-7. PubMed ID: 23122221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring tendon properties in mdx mice: cell viability and viscoelastic characteristics.
    Rizzuto E; Musarò A; Catizone A; Del Prete Z
    J Biomech; 2009 Oct; 42(14):2243-8. PubMed ID: 19665133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice.
    Shavlakadze T; White J; Hoh JF; Rosenthal N; Grounds MD
    Mol Ther; 2004 Nov; 10(5):829-43. PubMed ID: 15509501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice.
    Schertzer JD; Gehrig SM; Ryall JG; Lynch GS
    Am J Pathol; 2007 Oct; 171(4):1180-8. PubMed ID: 17823291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
    Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
    J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1.
    De Luca A; Pierno S; Liantonio A; Cetrone M; Camerino C; Fraysse B; Mirabella M; Servidei S; Rüegg UT; Conte Camerino D
    J Pharmacol Exp Ther; 2003 Jan; 304(1):453-63. PubMed ID: 12490622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage.
    Gehrig SM; Ryall JG; Schertzer JD; Lynch GS
    Exp Physiol; 2008 Nov; 93(11):1190-8. PubMed ID: 18567600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.
    Gehrig SM; van der Poel C; Hoeflich A; Naim T; Lynch GS; Metzger F
    Growth Horm IGF Res; 2012 Apr; 22(2):69-75. PubMed ID: 22424862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The passive mechanical properties of the extensor digitorum longus muscle are compromised in 2- to 20-mo-old mdx mice.
    Hakim CH; Grange RW; Duan D
    J Appl Physiol (1985); 2011 Jun; 110(6):1656-63. PubMed ID: 21415170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muscle-specific overexpression of IGF-I improves E-C coupling in skeletal muscle fibers from dystrophic mdx mice.
    Schertzer JD; van der Poel C; Shavlakadze T; Grounds MD; Lynch GS
    Am J Physiol Cell Physiol; 2008 Jan; 294(1):C161-8. PubMed ID: 17989207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive mechanical properties of maturing extensor digitorum longus are not affected by lack of dystrophin.
    Wolff AV; Niday AK; Voelker KA; Call JA; Evans NP; Granata KP; Grange RW
    Muscle Nerve; 2006 Sep; 34(3):304-12. PubMed ID: 16770793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice.
    Gregorevic P; Plant DR; Lynch GS
    Muscle Nerve; 2004 Sep; 30(3):295-304. PubMed ID: 15318340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
    St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
    Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice.
    Schertzer JD; Ryall JG; Lynch GS
    Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E499-505. PubMed ID: 16621899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neopterin/7,8-dihydroneopterin is elevated in Duchenne muscular dystrophy patients and protects mdx skeletal muscle function.
    Lindsay A; Schmiechen A; Chamberlain CM; Ervasti JM; Lowe DA
    Exp Physiol; 2018 Jul; 103(7):995-1009. PubMed ID: 29791760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery.
    Abmayr S; Gregorevic P; Allen JM; Chamberlain JS
    Mol Ther; 2005 Sep; 12(3):441-50. PubMed ID: 16099410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGF-II ameliorates the dystrophic phenotype and coordinately down-regulates programmed cell death.
    Smith J; Goldsmith C; Ward A; LeDieu R
    Cell Death Differ; 2000 Nov; 7(11):1109-18. PubMed ID: 11139285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice.
    Barton ER; Morris L; Musaro A; Rosenthal N; Sweeney HL
    J Cell Biol; 2002 Apr; 157(1):137-48. PubMed ID: 11927606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 3 months mild functional test regime does not affect disease parameters in young mdx mice.
    van Putten M; de Winter C; van Roon-Mom W; van Ommen GJ; 't Hoen PA; Aartsma-Rus A
    Neuromuscul Disord; 2010 Apr; 20(4):273-80. PubMed ID: 20307983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice.
    Messina S; Bitto A; Aguennouz M; Minutoli L; Monici MC; Altavilla D; Squadrito F; Vita G
    Exp Neurol; 2006 Mar; 198(1):234-41. PubMed ID: 16410003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.